Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK'S-first in man study of the Passeo-18 LUX drug …
T Zeller, U Beschorner, E Pilger, M Bosiers… - JACC: Cardiovascular …, 2015 - jacc.org
Objectives: The aim of BIOLUX P-II (BIOTRONIK'S–First in Man study of the Passeo-18 LUX
drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in …
drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in …
Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized …
Objectives: This study sought to report the results of a prospective randomized controlled
trial comparing paclitaxel-coated balloons (PCB) versus drug-eluting stents (DES) in long …
trial comparing paclitaxel-coated balloons (PCB) versus drug-eluting stents (DES) in long …
Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN. PACT SFA randomized trial
PA Schneider, JR Laird, G Tepe… - Circulation …, 2018 - Am Heart Assoc
Background—Randomized controlled trials have reported favorable 1-year outcomes with
drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease …
drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease …
Drug‐coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal …
O Iida, Y Soga, K Urasawa, S Saito… - Catheterization and …, 2019 - Wiley Online Library
Objectives To assess the longer‐term safety and efficacy of the IN. PACT Admiral (MDT‐
2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic …
2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic …
12-month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment
S Steiner, A Willfort-Ehringer, H Sievert, V Geist… - JACC: Cardiovascular …, 2018 - jacc.org
Objectives: The authors sought to evaluate the performance of the Ranger paclitaxel-coated
balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months …
balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months …
Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of infrapopliteal artery lesions (AcoArt II–BTK)
X Jia, B Zhuang, F Wang, Y Gu… - Journal of …, 2021 - journals.sagepub.com
Purpose To compare the safety and efficacy of drug-coated balloon (DCB) vs uncoated
balloon angioplasty in the treatment of de novo and restenotic infrapopliteal lesions in …
balloon angioplasty in the treatment of de novo and restenotic infrapopliteal lesions in …
Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions: five-year outcomes from the IN. PACT SFA randomized trial
JA Laird, PA Schneider, MR Jaff… - Circulation …, 2019 - Am Heart Assoc
Background: While randomized trials have demonstrated the superiority of drug-coated
balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA) in …
balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA) in …
Low-dose paclitaxel–coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the …
H Schroeder, M Werner, DR Meyer, P Reimer… - Circulation, 2017 - Am Heart Assoc
Background: Numerous studies have reported favorable outcomes using drug-coated
balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial …
balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial …
Drug-coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal …
O Iida, Y Soga, K Urasawa, S Saito… - Journal of …, 2018 - journals.sagepub.com
Purpose: To assess the safety and effectiveness of the MDT-2113 (IN. PACT Admiral) drug-
coated balloon (DCB) for the treatment of de novo and native artery restenotic lesions in the …
coated balloon (DCB) for the treatment of de novo and native artery restenotic lesions in the …
First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome
A Schmidt, M Piorkowski, M Werner, M Ulrich… - Journal of the American …, 2011 - jacc.org
Objectives: The purpose of this study was to investigate the efficacy of drug-eluting balloons
(DEBs) in the treatment of long infrapopliteal lesions with regard to the short-term restenosis …
(DEBs) in the treatment of long infrapopliteal lesions with regard to the short-term restenosis …